Skip to main content

Avapag 20 mg ( Avatrombopag)

Introduction

Avapag 20 mg is identified on this website as a product containing avatrombopag, an oral thrombopoietin receptor agonist (TPO-RA).

Avatrombopag stimulates platelet production by activating thrombopoietin receptors involved in megakaryocyte development in the bone marrow.

It is used in specific medical settings involving thrombocytopenia, including chronic immune thrombocytopenia (ITP) in certain adults and thrombocytopenia associated with chronic liver disease before a scheduled medical procedure.

This page provides general prescribing-related information about avatrombopag, including its therapeutic uses, dosage considerations, warnings, precautions, interactions and monitoring requirements.

Important product identification notice: The information below describes the established clinical and prescribing information for avatrombopag and, where specified, the reference tablet product. It is not an independently verified official prescribing label for Avapag. The exact Avapag formulation, manufacturer, authorization and product-specific instructions must be confirmed through its own official documentation.

1. Medicine Identification

InformationDetails
Product nameAvapag
Stated strength20 mg
Active ingredientAvatrombopag
Drug classThrombopoietin receptor agonist
Therapeutic categoryHematological medicine
Route of administrationOral for the reference tablet formulation
Main pharmacological actionStimulation of platelet production
Main treatment areasSelected forms of thrombocytopenia

The information in this table identifies the product as described on this website. Product-specific details should be checked against its packaging and official documentation.

2. Therapeutic Indications

Avatrombopag has established adult treatment uses in two important clinical settings.

A. Thrombocytopenia Associated With Chronic Liver Disease

Avatrombopag is used in certain adults with chronic liver disease who have thrombocytopenia and are scheduled to undergo a medical procedure.

The treatment helps increase platelet counts before the procedure.

The clinical objective is to achieve an appropriate platelet count for the planned intervention and potentially reduce the need for platelet transfusion.

Avatrombopag does not treat the underlying chronic liver disease.

B. Chronic Immune Thrombocytopenia

Avatrombopag is also used in adults with chronic immune thrombocytopenia who have had an insufficient response to previous treatment.

ITP is an autoimmune condition in which the immune system mistakenly attacks platelets, resulting in reduced platelet counts.

Avatrombopag stimulates platelet production in the bone marrow and can help increase circulating platelet levels.

It does not eliminate the underlying autoimmune process.

3. Mechanism of Action

Avatrombopag is a small-molecule thrombopoietin receptor agonist.

It activates the thrombopoietin receptor, also known as c-Mpl, which is involved in platelet production.

Its mechanism includes:

  1. Activation of thrombopoietin receptors.
  2. Stimulation of megakaryocyte precursor-cell proliferation.
  3. Promotion of megakaryocyte differentiation.
  4. Increased platelet production in the bone marrow.
  5. An increase in circulating platelet counts.

Avatrombopag does not compete with natural thrombopoietin for the same receptor-binding site. Its action can be additive with natural thrombopoietin.

4. Dosage and Administration

The appropriate avatrombopag dosage depends on the medical indication and the patient’s platelet count.

The following information describes the reference Doptelet tablet prescribing regimens. These are not confirmed Avapag-specific dosing instructions.

Dosage for Chronic Liver Disease

For adults with thrombocytopenia associated with chronic liver disease who are scheduled for a medical procedure, the reference tablet regimen is based on the platelet count before treatment.

Baseline platelet countReference daily doseDuration
Below 40 × 10⁹/L60 mg5 consecutive days
40 to below 50 × 10⁹/L40 mg5 consecutive days

The reference regimen begins 10–13 days before the scheduled procedure.

The procedure is generally planned 5–8 days after the final dose.

Platelet counts should be checked before treatment and on the day of the procedure.

Dosage for Chronic ITP in Adults

The reference adult tablet regimen starts at:

– 20 mg once daily with food.

The dose may be adjusted according to platelet-count response.

The maximum recommended adult dose in the reference prescribing information is 40 mg per day.

The objective is to maintain an appropriate platelet count using the lowest effective dose.

Important: Do not calculate or select an Avapag dosage from this information. Follow the verified product instructions and the prescribing clinician’s directions.

5. Administration Instructions

For the reference tablet formulation, the medicine is taken orally with food.

General administration considerations include:

  • Follow the prescribed dosing schedule.
  • Take the medicine according to the product instructions.
  • Do not take additional tablets without medical advice.
  • Do not independently change the dosing frequency.
  • Follow the missed-dose instructions for the specific indication.
  • Attend recommended platelet-count monitoring appointments.

The exact administration instructions for Avapag must be confirmed from its own official product information.

6. Contraindications

A contraindication is a condition or circumstance in which a medicine should not be used because the potential risks outweigh the expected benefits.

The appropriate contraindications for a particular product must be established from its official prescribing information.

Before prescribing avatrombopag, healthcare professionals should evaluate:

  • Previous serious allergic reactions to the active ingredient or product components.
  • History of thrombotic or thromboembolic events.
  • Conditions associated with increased blood-clotting risk.
  • Underlying liver disease.
  • Other significant medical conditions.
  • Potential medicine interactions.

Patients should provide a complete medical history before treatment.

7. Important Warnings and Precautions

Thrombotic and Thromboembolic Complications

Avatrombopag stimulates platelet production. An excessive platelet response may increase the risk of thrombotic or thromboembolic complications.

Patients with a history of blood clots or other clotting risk factors require careful assessment.

Possible warning symptoms include:

  • Sudden chest pain.
  • Difficulty breathing.
  • Pain or swelling in one leg.
  • Sudden weakness or numbness.
  • Difficulty speaking.
  • Sudden changes in vision.

These symptoms require urgent medical assessment.

Platelet Count Monitoring

Platelet counts should be monitored throughout treatment according to the prescribed schedule.

The objective is not to normalize platelet counts but to achieve an appropriate therapeutic response.

Healthcare professionals may adjust treatment based on blood-test results.

Chronic Liver Disease

Patients with chronic liver disease may have complex bleeding and clotting risks.

Treatment decisions should consider the underlying liver condition, platelet count, planned procedure and other clinical factors.

Pregnancy

Pregnancy should be discussed with a healthcare professional before treatment.

The reference product prescribing information includes a warning concerning potential fetal harm.

Breastfeeding

The reference product information advises against breastfeeding during treatment.

Patients should discuss the benefits and risks of treatment and breastfeeding with their healthcare professional.

8. Adverse Reactions

Avatrombopag may cause adverse reactions. Their frequency and type can vary according to the treatment indication.

Commonly Reported Reactions in Chronic Liver Disease

Reported reactions with the reference product include:

  • Fever.
  • Abdominal pain.
  • Nausea.
  • Headache.
  • Fatigue.
  • Peripheral edema.

Commonly Reported Reactions in Chronic ITP

Reported reactions include:

  • Headache.
  • Fatigue.
  • Bruising.
  • Epistaxis.
  • Upper respiratory tract infection.
  • Arthralgia.
  • Gingival bleeding.
  • Petechiae.
  • Nasopharyngitis.

Patients should inform their healthcare professional about persistent, worsening or unusual symptoms.

Serious Adverse Events

Important safety concerns include thrombotic and thromboembolic complications.

Seek urgent medical assistance if symptoms suggestive of a blood clot develop.

9. Drug Interactions

Avatrombopag exposure may be affected by medicines that influence drug-metabolizing enzymes.

Important pathways include:

  • CYP2C9.
  • CYP3A4.

Medicines that inhibit or induce these enzymes may alter avatrombopag exposure.

Examples of medicine categories requiring review include:

  • Certain antifungal medicines.
  • Some antibiotics.
  • Certain anticonvulsants.
  • Other medicines that affect CYP2C9 or CYP3A4 activity.

Healthcare professionals should review the patient’s complete medication list before treatment.

Do not discontinue another medicine or modify avatrombopag dosing without professional advice.

10. Use in Special Populations

Older Adults

Treatment decisions should consider overall health, medical history, other medicines and treatment response.

Pediatric Patients

The U.S. reference-product information includes specific provisions for certain pediatric patients with persistent or chronic ITP. Different formulations and dosing instructions may apply according to age.

This information does not establish pediatric authorization for Avapag.

Pregnancy

Patients who are pregnant or planning pregnancy should consult their healthcare professional before using avatrombopag.

Breastfeeding

The reference product information advises against breastfeeding during treatment.

Patients With Liver Disease

Avatrombopag has an established use in certain adults with chronic liver disease-associated thrombocytopenia before a scheduled procedure. Treatment requires appropriate clinical evaluation.

11. Clinical Pharmacology

Pharmacodynamics

Avatrombopag activates thrombopoietin receptors and stimulates platelet production.

For the reference tablet product, platelet counts may begin increasing approximately 3–5 days after treatment starts, with peak increases generally observed around 10–13 days.

Individual responses may vary.

Pharmacokinetics

Avatrombopag is administered orally in the reference tablet formulation.

Its absorption, distribution, metabolism and elimination influence the amount of medicine available in the body.

Factors such as food intake and medicines affecting CYP2C9 or CYP3A4 may influence drug exposure.

The precise pharmacokinetic characteristics of a particular Avapag formulation should be confirmed from its official documentation.

12. Monitoring Requirements

Monitoring is an important part of safe avatrombopag treatment.

Chronic Liver Disease

For the reference product:

  • Obtain a platelet count before treatment.
  • Repeat the platelet count on the day of the scheduled procedure.

Chronic ITP

For the reference adult regimen:

  • Monitor platelet counts weekly until a stable response is achieved.
  • Monitor monthly once platelet counts are stable.
  • Continue weekly monitoring for at least four weeks after treatment is discontinued.

Additional monitoring may be appropriate depending on the patient’s clinical condition.

13. Overdose Information

Taking more avatrombopag than prescribed may increase the risk of adverse effects and excessive platelet-count elevation.

If an overdose is suspected:

  1. Contact a healthcare professional immediately.
  2. Seek urgent medical assessment when necessary.
  3. Keep the medicine packaging available.
  4. Provide information about the amount and time of ingestion.
  5. Do not attempt to manage the overdose by independently changing future doses.

14. Storage and Handling

Storage instructions should be obtained from the official product packaging and patient information leaflet.

General medicine-handling precautions include:

  • Keep the medicine away from children.
  • Store it according to the stated product requirements.
  • Check the expiry date before use.
  • Avoid using damaged or suspicious packaging.
  • Do not use expired medicine.
  • Ask a pharmacist how to handle unused or unwanted tablets.

Do not assume specific storage temperatures or conditions without verified product information.

15. Important Information for Healthcare Professionals

Before initiating avatrombopag treatment, healthcare professionals should evaluate:

  • The indication for treatment.
  • Baseline platelet count.
  • Previous treatment history.
  • Risk factors for thrombosis.
  • Other medical conditions.
  • Current prescription medicines.
  • Potential drug interactions.
  • Pregnancy and breastfeeding considerations.
  • Monitoring requirements.

The lowest effective dose should be used according to the applicable prescribing information.

Treatment should be individualized and monitored appropriately.

Frequently Asked Questions About Prescribing Information

1. What is Avapag 20 mg prescribed for?

Avapag is identified on this website as containing avatrombopag. Established adult uses of avatrombopag include certain cases of chronic liver disease-associated thrombocytopenia before a scheduled procedure and chronic ITP after insufficient response to previous treatment.

2. What is the active ingredient in Avapag?

The stated active ingredient is avatrombopag.

3. What drug class does avatrombopag belong to?

Avatrombopag belongs to the thrombopoietin receptor agonist class.

4. What is the reference adult dosage for chronic ITP?

The reference adult tablet regimen starts at 20 mg once daily with food. Dose adjustments depend on platelet-count response. This is not a confirmed Avapag-specific dosage.

5. Is avatrombopag associated with blood clots?

Yes. Thrombotic and thromboembolic complications are important safety concerns associated with treatment.

6. Does avatrombopag require platelet monitoring?

Yes. Platelet counts should be monitored according to the indication and treatment response.

7. Can avatrombopag interact with other medicines?

Yes. Certain medicines affecting CYP2C9 and CYP3A4 may alter avatrombopag exposure. A healthcare professional should review all medicines before treatment.

8. Can avatrombopag be used during pregnancy?

Pregnancy requires careful medical assessment. The reference product prescribing information warns about potential fetal harm.

9. Can avatrombopag be taken with food?

The reference tablet product is taken with food. Follow the instructions for the specific product prescribed.

10. Is this the official Avapag prescribing label?

No. This page is an educational overview of avatrombopag prescribing considerations. The official Avapag prescribing information must be obtained and verified separately.

Final Prescribing Information Notice

The information on this page is intended to help readers understand important prescribing considerations associated with avatrombopag.

It should not be interpreted as a substitute for the official prescribing information for Avapag 20 mg.

Product-specific instructions, manufacturer details, regulatory authorization, formulation and approved indications must be verified through appropriate documentation.

Healthcare professionals should always consult the applicable official prescribing information before prescribing or administering a medicine.

Medical Disclaimer

This page is provided for general educational purposes only. It does not constitute medical advice, a prescription or a recommendation to begin treatment.

Avatrombopag requires appropriate medical supervision and platelet-count monitoring. It may cause adverse reactions and is associated with thrombotic risks.

Patients should consult a qualified healthcare professional before starting, changing or discontinuing treatment.